| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5579438 | Seminars in Radiation Oncology | 2017 | 11 Pages |
Abstract
This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shankar MBBS, PhD, FRANZCR, Ben J. MD, PhD,